


# Guide to Routine MCV4<sup>a</sup> Immunization in Adolescents 11–18 Years of Age<sup>b</sup>



## FOOTNOTES

<sup>a</sup> MCV4 (meningococcal conjugate vaccine 4-valent or meningococcal ACWY vaccine) helps protect against meningococcal disease resulting from infection with serogroup A,C,W, or Y.

<sup>b</sup> For more detailed information on the use of meningococcal vaccines, including guidance related to vaccination of persons at increased risk for infection, go to [www.cdc.gov/mmwr/pdf/rr/rr6202.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf).

<sup>c</sup> If immunization records cannot be located within a reasonable time, the patient should be considered unvaccinated and started on the age-appropriate vaccine schedule. (Reference: Centers for Disease Control and Prevention [CDC]. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. *MMWR*. 2011;60[RR-2]:1-64.)

## Additional Information

### Administration of MCV4

- MCV4 may be given up to 21 years of age as catch-up vaccination for those who have not received a dose after their 16th birthday.
- Routine MCV4 vaccination of healthy persons not at increased risk for exposure to *Neisseria meningitidis* is not recommended for those older than 21 years of age.

### Persons with human immunodeficiency virus (HIV)

- Adolescents 11 through 18 years of age with HIV infection should receive a 2-dose primary series, with at least 8 weeks between doses.
- They should also receive a booster dose at 16 years of age if they received their primary series before their 16th birthday.

### Persons at increased risk for meningococcal disease for whom MCV4 immunization is recommended

- First-year college students through 21 years of age living in a residential hall
- People with a persistent complement component deficiency or functional or anatomic asplenia
- People present during an outbreak caused by a vaccine serogroup
- Microbiologists routinely working with *Neisseria meningitidis* isolates
- Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic
- United States military recruits

For dosing recommendations, refer to the CDC guidelines ([www.cdc.gov/mmwr/pdf/rr/rr6202.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf)) or go to [www.immunize.org/catg.d/p2018.pdf](http://www.immunize.org/catg.d/p2018.pdf).

### Contraindications and precautions

- **Contraindications:** history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of meningococcal vaccine or to a meningococcal vaccine component. For information on vaccine components, refer to the manufacturer's package insert ([www.immunize.org/packageinserts](http://www.immunize.org/packageinserts)) or go to [www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf).
- **Precaution:** moderate or severe acute illness with or without fever. (Refer to manufacturer's package insert for additional precautions, e.g., potential for diminished immune response in persons with altered immunocompetence.)